Cloning and functional expression of human kynurenine 3-monooxygenase  by Alberati-Giani, Daniela et al.
FEBS 18775 FEBS Letters 410 (1997) 407-412 
Cloning and functional expression of human kynurenine 
3-monooxygenase 
Daniela Alberati-Giania*, Andrea M. Cesuraa, Clemens Brogera, William D. Warrenb, 
Stephan R6vera, Pari Malherbea 
^Pharmaceutical Division, Preclinical Research, F. Hoffmann-La Roche Ltd, CH-4070 Basel, Switzerland 
hPeter MacCallum Cancer Institute, St. Andrew Place, East Melbourne, Vic. 3002, Australia 
Received 7 April 1997 
Abstract Kynurenine 3-monooxygenase, an NADPH-depend-
ent flavin monooxygenase, catalyses the hydroxylation of L-
kynurenine to L-3-hydroxykynurenine. By hybridization screen-
ing using a cDNA probe encoding the entire exon 2 of Drosophila 
melanogaster kynurenine 3-monooxygenase, we isolated a 2.0 kb 
cDNA clone coding for the corresponding human liver enzyme. 
The deduced amino acid sequence of the human protein consists 
of 486 amino acids with a predicted molecular mass of 55 762 Da. 
Transfection of the human cDNA in HEK-293 cells resulted in 
the functional expression of the enzyme with kinetic properties 
similar to those found for the native human protein. RNA blot 
analysis of human tissues revealed the presence of a major 
mRNA species of ~ 2.0 kb in liver, placenta and kidney. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The interest in the kynurenine pathway has grown steadily 
over the past few years and stems from several findings sug-
gesting a role of this metabolic route in some pathological 
conditions. Accumulation of kynurenine metabolites may, in 
fact, constitute a potentially hazardous event. Quinolinic acid 
is a potent excitotoxin [1] and its overproduction by activated 
brain-invading macrophages and/or microglial cells has been 
linked to neuronal damage occurring in neuroinflammatory 
disorders [2^4]. Relatively high concentrations of L-3-hy-
droxykynurenine may also be neurotoxic and a recent report 
suggests that this metabolite mediates neuronal cell death 
through H2O2 production [5]. In addition, kynurenic acid 
may represent an endogenous neuroprotectant species [1]. 
On the other hand, because of the antioxidant properties of 
some L-tryptophan metabolites, activation of the kynurenine 
pathway may represent a defence against the excessive pro-
duction of reactive oxygen and nitrogen species in inflamma-
tion [6]. 
The primary structure of most enzymes constituting this 
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metabolic route has been elucidated. These include trypto-
phan 2,3-dioxygenase [7], indoleamine 2,3-dioxygenase [8], ky-
nureninase [9], 3-hydroxyanthranilic-acid dioxygenase [10] and 
kynurenine aminotransferase isoforms [11-13]. 
Kynurenine 3-monooxygenase (KMO, EC 1.14.13.9) is an 
NADPH-dependent flavin monooxygenase, catalysing the hy-
droxylation of the L-tryptophan metabolite L-kynurenine to 
form L-3-hydroxykynurenine. KMO is a membrane protein 
located on the outer membrane of mitochondria [14]. Tissue 
distribution studies have revealed that, in rats, highest enzyme 
activity is found in kidney and liver, with brain having the 
least activity in comparison to peripheral organs [14]. Nota-
bly, KMO appears to be upregulated in inflammatory condi-
tions [3,15]. It has been proposed that inhibitors of KMO may 
provide new neuroprotective agents and KMO inhibitors have 
been found to protect against chemically and electrically in-
duced seizures in rodents and to reduce infarct size in a global 
ischemia model in gerbils [16,17]. 
Recently, genomic DNA analysis of chromosome 2 of Dro-
sophila melanogaster has resulted in the identification of the 
cinnabar gene region (accession number U56245) encoding 
KMO from this insect species [18]. By using a cDNA probe 
derived from the D. melanogaster KMO (dmKMO) gene, we 
report here the molecular cloning and the functional expres-
sion of a cDNA clone encoding human KMO (hKMO). 
2. Materials and methods 
2.1. Isolation of human KMO cDNA 
To generate a hybridization probe for screening, we performed 
PCR amplification of the D. melanogaster genomic DNA %K8 clone 
(1 ng) [18] using 10 pmol each of sense and antisense primers (sense: 
5'-GGGTTCTCTGGCAGCCTTGAACT-3', antisense: 5'-CTCCA-
CATAATTGTACATGGCCAG-3') as previously described [10]. 
The final PCR product of 1042 bp (dmKMO cDNA) was isolated 
and subcloned into the pBluescript vector. A human liver cDNA 
library constructed in the X uni-zap vector (Stratagene, La Jolla, 
CA) was screened following previously described procedures [19]. 
Briefly, the filters were hybridized at low stringency with a 32P-labeled 
nick-translated 1042 bp dmKMO cDNA probe for 24 h at 37°C in 
6X NET (1 X NET= 150 mM NaCl, 15 mM Tris-HCl, pH 8.3, 1 mM 
EDTA), 1X Denhardt's solution (0.02% bovine serum albumin, 
0.02% Ficoll, 0.02% polyvinylpyrrolidone), 0.1% SDS, 1 mM 
Na4P207, 100 mM ATP, 20% deionized formamide, and 500 ug/ml 
salmon sperm DNA. The filters were then washed twice at room 
temperature for 1 h in 6 X SSC (1 X SSC= 150 mM NaCl, 15 mM 
sodium citrate, pH 7.4), containing 0.1%> SDS. 
A human KMO partial cDNA (hKMOF4), obtained from low 
stringency screening, served then as hybridization probe for screening 
the same human liver cDNA library, at higher stringency [19]. From a 
total of 2X106 plaques, 15 positive clones were obtained and purified 
through an additional round of screening at lower density plaque. 
Bluescript plasmids (pBSK, Stratagene), carrying the cDNA inserts, 
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were isolated from positive phages via in vivo excision. The nucleotide 
sequence of the cDNA clones was determined by automated cycle 
sequencing (Applied Biosystems, California). 
2.2. Northern blot analysis 
Multiple tissue Northern blots from different human tissues were 
purchased from Clontech. After prehybridization for 4 h at 42°C, the 
RNA blots were hybridized for 18 h with a 32P-labeled nick-translated 
PCR derived 739 bp cDNA probe (nucleotides 625-1364) as previ-
ously described [10]. A 32P-labeled nick-translated PCR-amplifled 
fragment of human S12 ribosomal protein was used [9] as an internal 
standard probe. The blots were exposed to X-ray film for 22 h. 
2.3. Expression of recombinant hKMO in HEK-293 cells 
The 2.0 kb cDNA encoding hKMO was subcloned in the EcoRl site 
of the expression vector pBC/CMV [20], placing transcription of the 
cDNA under the control of the strong immediate early promoter of 
human cytomegalovirus. Human embryonic kidney fibroblast cells 
(HEK-293, ATCC CRL 1573) were transfected as previously de-
scribed [10]. Two days after transfection, the cells were harvested 
and washed twice with phosphate-buffered saline and stored at 
—80°C until analysis. For enzyme activity determination, the trans-
fected cells were homogenized in 1 ml of 10 mM potassium phosphate 
buffer, pH 7.4, containing 0.5 mM phenylmethanesulfonyl fluoride. 
2.4. Determination of KMO activity 
KMO activity was measured using a microplate version of the ra-
dioenzymatic method described by Erickson et al. [14], based on the 
release of tritiated water after hydroxylation of L-[3-3H]kynurenine. 
The assay was performed in a final volume of 100 |xl of 0.1 M potas-
sium phosphate buffer, pH 7.4. The reaction mixture consisted of 100 
|lM L-kynurenine sulfate, 0.2 (xCi of L-[3-3H]kynurenine (spec. act. 
14.4-16.1 Ci/mmol; 1 Ci = 37 GBq, F. Hoffmann-La Roche, Basel), 
200 uM NADPH, 0.4 U/ml glucose-6-phosphate dehydrogenase and 
3 mM glucose-6-phosphate. After addition of 5-10 u.1 of the cell ho-
mogenates, the plate was incubated for 10 min at 37°C. Incubation 
1 GAATTCGGCACGAGCAGAAGCAACAATAATTGTGAAAAATACTTCAGCAGTTATGGACTCATCTGTCATTCAAAGGAAAA 80 
1 M D S S V I Q R K K 1 0 
81 AAGTAGCTGTCATTGGTGGTGGCTTGGTTGGCTCATTACAAGCATGCTTTCTTGCAAAGAGGAATTTCCAGATTGATGTA 160 
11 V A V I G G G L V G S L Q A C F L A K R N F Q I D V 36 
161 TATGAAGCTAGGGAAGATACTCGAGTGGCTACCTTCACACGTGGAAGAAGCATTAACTTAGCCCTTTCTCATAGAGGACG 240 
3 7 Y E A R E D T R V A T F T R G R S I N L A L S H R G R 63 
241 ACAAGCCTTGAAAGCTGTTGGCCTGGAAGATCAGATTGTATCCCAAGGTATTCCCATGAGAGCAAGAATGATCCACTCTC 320 
64 Q A L K A V G L E D Q I V S Q G I P M R A R M I H S L 90 
321 TTTCAGGAAAAAAGTCTGCAATTCCCTATGGGACAAAGTCTCAGTATATTCTTTCTGTAAGCAGAGAAAATCTAAACAAG 400 
91 S G K K S A I P Y G T K S Q Y I L S V S R E N L N K 116 
401 GATCTATTGACTGCTGCTGAGAAATACCCCAATGTGAAAATGCACTTTAACCACAGGCTGTTGAAATGTAATCCAGAGGA 480 
117 D L L T A A E K Y P N V K M H F N H R L L K C N P E E 143 
481 AGGAATGATCACAGTGCTTGGATCTGACAAAGTTCCCAAAGATGTCACTTGTGACCTCATTGTAGGATGTGATGGAGCCT 560 
144 G M I T V L G S D K V P K D V T C D L I V G C D G A Y 170 
561 ATTCAACTGTCAGATCTCACCTGATGAAGAAACCTCGCTTTGATTACAGTCAGCAGTACATTCCTCATGGGTACATGGAG 640 
171 S T V R S H L M K K P R F D Y S Q Q Y I P H G Y M E 196 
641 TTGACTATTCCACCTAAGAACGGAGATTATGCCATGGAACCTAATTATCTGCATATTTGGCCTAGAAATACCTTTATGAT 720 
197 L T I P P K N G D Y A M E P N Y L H I W P R N T F M M 223 
721 GATTGCACTTCCTAACATGAACAAATCATTCACATGTACTTTGTTCATGCCCTTTGAAGAGTTTGAAAAACTTCTAACCA 800 
224 I A L P N M N K S F T C T L F M P F E E F E K L L T S 250 
801 GTAATGATGTGGTAGATTTCTTCCAGAAATACTTTCCGGATGCCATCCCTCTAATTGGAGAGAAACTCCTAGTGCAAGAT 880 
251 N D V V D F F Q K Y F P D A I P L I G E K L L V Q D 276 
881 TTCTTCCTGTTGCCTGCCCAGCCCATGATATCTGTAAAGTGCTCTTCATTTCACTTTAAATCTCACTGTGTACTGCTGGG 960 
277 F F L L P A Q P M I S V K C S S F H F K S H C V L L G 303 
961 AGATGCAGCTCATGCTATAGTGCCGTTTTTTGGGCAAGGAATGAATGCGGGCTTTGAAGACTGCTTGGTATTTGATGAGT 1040 
304 D A A H A I V P F F G Q G M N A G F E D C L V F D E L 330 
1041 TAATGGATAAATTCAGTAACGACCTTAGTTTGTGTCTTCCTGTGTTCTCAAGATTGAGAATCCCAGATGATCACGCGATT 1120 
331 M D K F S N D L S L C L P V F S R L R I P D D H A I 356 
1121 TCAGACCTATCCATGTACAATTACATAGAGATGCGAGCACATGTCAACTCAAGCTGGTTCATTTTTCAGAAGAACATGGA 1200 
357 S D L S M Y N Y I E M R A H V N S S W F I F Q K N M E 383 
1201 GAGATTTCTTCATGCGATTATGCCATCGACCTTTATCCCTCTCTATACAATGGTCACTTTTTCCAGAATAAGATACCATG 1280 
384 R F L H A I M P S T F I P L Y T M V T F S R I R Y H E 410 
1281 AGGCTGTGCAGCGTTGGCATTGGCAAAAAAAGGTGATAAACAAAGGACTCTTTTTCTTGGGATCACTGATAGCCATCAGC 1360 
411 A V Q R W H W Q K K V I N K G L F F L G S L I A I S 436 
1361 AGTACCTACCTACTTATACACTACATGTCACCACGATCTTTCCTCTGCTTGAGAAGACCATGGAACTGGATAGCTCACTT 1440 
437 S T Y L L I H Y M S P R S F L C L R R P W N W I A H F 463 
1441 CCGGAATACAACATGTTTCCCCGCAAAGGCCGTGGACTCCCTAGAACAAATTTCCAATCTCATTAGCAGGTGATAGAAAG 1520 
464 R N T T C F P A K A V D S L E Q I S N L I S R * 486 
1521 GTTTTGTGGTAGCAAATGCATGATTTCTCTGTGACCAAAATTAAGCATGAAAAAAATGTTTCCATTGCCATATTTGATTC 1600 
1601 ACTAGTGGAAGATAGTGTTCTGCTTATAATTAAACTGAATGTAGAGTATCTCTGTATGTTAATTGCAATTACTGGTTGGG 1680 
1681 GGGTGCATTTTAAAAGATGAAACATGCAGCTTCCCTACATTACACACACTCAGGTTGAGTCATTCTAACTATAAAAGTGC 1760 
1761 AATGACTAAGATCCTTCACTTCTCTGAAAGTAAGGCCCTAGATGCCTCAGGGAAGACAGTAATCATGCCTTTTCTTTAAA 1840 
1841 AGACACAATAGGACTCGCAACAGCATTGACTCAACACCTAGGACTAAAAATCACAACTTAACTAGCATGTTAACTGCACT 1920 
1921 TTTCATTACGTGAATGGAACTTACCTAACCACAGGGCTCAGACTTACTAGATAAAACCAGAAATGGAAATAAGGAATTC 1999 
Fig. 1. Nucleotide and predicted amino acid sequence of cloned human liver KMO (hKMOC15 cDNA clone). The deduced amino acid se-
quence of the encoded polypeptide is shown in single-letter code below the nucleotide sequence and is numbered beginning with the initiating 
methionine. Nucleotides are numbered in the 5' to 3' direction. The asterisk denotes the 3'-terminal stop codon. 
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Fig. 2. Kinetic properties of recombinant hKMO expressed in 
HEK-293 cells. Saturation curves were calculated by fitting the data 
to Michaelis-Menten equation using the Ultrafit (Biosoft) computer 
program. Data are the means ± SEM of three experiments. 
was terminated by addition of 150 ul of a 10% (w/v) suspension of 
activated charcoal (Norit A) and, after shaking for 2 min, the plates 
were centrifuged for 10 min at 2000 Xg. An aliquot (50 ui) of the 
sample was then transferred to the well of a second microtiter plate 
containing 200 ul/well of scintillation fluid (Microscint 40, Packard). 
After vigorous shaking, the plates were counted for radioactivity 
using a Top-Count (Packard) counter. 
3. Results and discussion 
3.1. Molecular cloning of human KMO cDNA 
To isolate a c D N A encoding hKMO, we generated by PCR 
amplification a 1042 bp c D N A probe encoding the entire exon 
2 (nucleotides 4447-5488) [18] of K M O from D. melanogaster 
(see Section 2). The d m K M O c D N A probe was then used to 
screen a X. uni-zap c D N A library of human liver. In an initial 
screening of 1.2 X 106 recombinants at very low stringency, 
five weak positive clones were detected. Translation of the 
D N A sequence of the largest hybridizing clone (hKMOF4) 
was found to code for a peptide sequence of 315 amino acids 
with 65% similarity with the predicted amino acid sequence of 
d m K M O (not shown). This indicated that the isolated c D N A 
hKMO MDSSVIQRKKVAVIGGGLVGSLQACFLAKRNFQIDVYEAREDTR. . VATFTRGRSINLALSHRGRQALKAVGLE. . DQIVSQGIPMR 83 
Q21795 MPSVAIAGAGLVGALNACFFAQKGWDVSVYEFRKDIR. .TMKHVQGRSINLALSQRGKSALEAVGLK. .EYIVNQGVPLY 76 
dmKMO RDERHGRRRRVAVIGAGLVGSLAALNFARMGNHVDLYEYREDIR. . QALWQGRSINLALSQRGRKALAAVGLE . . QEVLATAIPMR 162 
YBJ8YEAST MSESVAIIGAGLVGCLAALAFSKEGYNVTLYDFRQDPRLDTTKNKNLKSINLAISARGIDALKSIDPDACEHILQDMIPMK 81 
Q21794 MPSWIAGGGLVGSANACFFGQKGWIVDVYESRFDPRGNHME. . NGKSINLALGVRAMSTMKRIGLK. .EKVIHIGVPIR 76 
Consensus V***G*GLVG * A * *Y- R D R *+SINLA* R* * * * ** **P* 
hKMO ARMIHSLSGK.K.SAIPYGTKSQYILSVSRENLNKDLLTAAEKYPNVKMHFNHR LLKCNPEEGMITVLGSDKVPKD 157 
Q21795 ARLIHNKDGK.TYSRQPYGKPGEHIVSINRRHLNEVMITQAEKSPNVKFFFEHKVKNVDYDKKQLWQCTSQPSKIPTFGNKSPPQE 162 
dmKMO GRMLHDVRGN.SSWLYDPINNQCLYSVGRRQLNEVLLNACDKLPNIRCHFEHKL TSANLREGSMEFRNPAKE 234 
YBJ8_YEAST GRMIHDLKGR. QESQL. YGLHGEAINSINRSVTNNSLLDELEK . STTELKFGHKLVKIEWTDDKQICHFAIGEDLKTPHTEK 160 
Q21794 DQIAHFGDTKGKLKRLPVLNDDDFILTINRQELSQILINEAEKYNNVKFHFNCKATKFDLKSESLIVQNSDNLST 151 
Consensus *H °* R L° 
hKMO VTCDLIVGCDGAYSTVRSHLMKKPRFDYSQQYIPHGYMELTIPPK NGDYAMEPNYLHTWPRNTFMMIALPNMNKS 232 
Q21795 HAEFHVEADLILACDGAYSAVRRSLMTIPRFDFSQEYIEHGYVELNIMAN NNEFAFEENVFHLWPRGHFTLIALANRDKT 242 
dmKMO AVAAH. .ADLIVGCDGAFSSVRQXXVRLPGFNYSQEYIETGYLELCIPSK SGDFQMPANYLHTWPRNTFMMIALPNQDKS 312 
YBJ8_YEAST YDFVIGCDGAYSATRSQMQRKVEMDFSQEYMNLRYIELYIPPTEEFKPNYGGNFAIAPDHLHIWPRHKFMLIALANSDGS 240 
Q21794 VDGDLFLACDGAHSSIRRSLLKAPGFNFSQKYSEFGYIDLSVNSTQQCDLKLGTHYS WRRRGIILVAIVNKDQS 225 
Consensus D **CDGA S R * :SQ Y Y*-L * : W R **A**N 
hKMO FTCTLFMPFEEFEKLL.TSNDVVDFFQKYFPDAIPLIGEKLLVQDFFLLPAQPMISVKCSSFHF. KSHCVXLGDAAHAIVPFFGQGM 317 
Q21795 FTVTIFAPFSEFEKHMSTSEDVLSFFEENFPDAFLLLGKEHIADTFNRVKPQPLVSIKCSPHSF. FDNLVLMGDAAHAMVPFYGQGM 328 
dmKMO FTVTLSMPFEIFAG. IQNQNOLLEFFKLNFRDALPLIGEQQLIKDFFKTRPQFLVSIKCRPYHY. ADKALILGDAAHAMVPYYGQGM 397 
YBJ8JYEAST FTSTFFGSKDQISDLITSKSRVREFLIENFPDIINIMDLDDAVKRFITYPKESLVCVNCKPYDVPGGKAILLGDAAHAMVPFYGOGM 327 
Q21794 LTVSMFATFSEFESNLVGPVESVLFFKNNFYEIFKILGEDHIRNTIARNKPQAIISVQCSQHVF. FDKLVLMGDAAHAMVPFNGQGV 311 
Consensus T ° * *
 F F _ * * * * * * * c ***GDAAHA*VP: GQG* 
hKMO NAGFEDCLVFDELMDKFSND.LSLCLPVFSRLRIPDDHAISDLSMYNYIEMRAHVNSSWFIFQK. . .NMERFLHAIMPSTFIPLYTM 400 
Q21795 NCGFEDCLVFSETLEEYGND.IAKAVKVYSDGRVNDAHSINDLAMYNYEELKDLVNKSSYKLRK. . .KFDTIMNSIFPKSWIPLYSM 411 
dmKMO NAGMEDVTLLTDILAK.QLP.LDETLALFTESRWQDAFAICDLAMYNYVEMRDLTKRWTFRLRK. . . WLDTLLFRLFP. GWIPLYNS 478 
YBJ8_YEAST NCGFEDVRILMALLKKHSGD.RSRAFTEYTQTRHKDLVSITELAKRNYKEMSHDVTSKRFLLRK...KLDALFSIIMKDKWIPLYTM 410 
Q21794 NCGFEDCLVXQEIMDQYEEDELEDVIKEYSKVRTNETNIINQMEWDVNLTLTSSVHGSLGWIREIRAHIKLLLCFIFPSS FTL 394 
Consensus N G E D * * :• R - I * * * :° 
hKMO VTF.SRIRYHEAVQRWHWQKKVINKGLFFLGSLIAISSTYLLIHYMSPRSFLCLRRPWNWIAHFRNTTCFPAKAVDSLEQISNLISR 486 
Q21795 VTF.SRIPYSEVIERRKRQDKILSRIMTTTSTLALIGAAAGIYVNRGKLGL 461 
dmKMO VSF.SSMPYRQCIANRKWQDQLLKRIFGAT.FLAAIVTGGAIYAQRFL 524 
YBJ8_YEAST ISFRSDISYSRALERAGKQTRILKFLESLTLGMLSIGGYKLFKFLTRERS 460 
Q21794 AAF.SREKYSEI. . . .ARKAQIVEKCTSLFTNVFIVFIISVISLFWYLLGYCRGNLQAYCLQCAWSGVCVQEVS 464 
Consensus * F S Y ** * * * 
Fig. 3. Multiple alignment of the amino acid sequence of human KMO with proteins from the SwissProt and translated EMBL databases. 
hKMO, human kynurenine 3-monooxygenase; dmKMO, kynurenine 3-monooxygenase from D. melanogaster; YBJ8_Yeast, hypothetical pro-
tein in ATP1-ROX3 intergenic region of S. cerevisiae; Q21794 and Q21795, two sequences contained in chromosome III of C. elegans. In the 
consensus sequence, upper-case letters and symbols indicate identical amino acids and amino acids conserved in their physico-chemical proper-
ties, respectively; *, hydrophobic amino acids; :, aromatic amino acids; °, polar amino acids; +, positively charged amino acids; —, negatively 
charged amino acids. Note that the KMO amino acid sequence of D. melanogaster, shown in the figure, starts with the Arg at position 80. 
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Fig. 4. Northern-blot hybridization of poly (A)-rich RNAs from various human tissues. The blot was hybridized with a 32P-labeled nick-trans-
lated 739 bp hKMO cDNA and ribosomal S12 cDNA as internal standard. The scale on the ordinate indicates kilobases as determined by 
RNA size markers. The arrows indicate KMO and S12 mRNAs. The blot was exposed to X-ray film for 22 h. 
was likely a partial sequence of hKMO. To isolate a full 
length clone of hKMO, the human liver A, uni-zap cDNA 
library was submitted to a second screening with the 
hKMOF4 human partial cDNA probe. Fifteen positive clones 
were identified after screening of 2 X 106 plaques at high strin-
gency. The inserts from the positive clones were excised from 
pBluescript and, after analysis by Southern blot, were found 
to range from 700 to 5000 bp in size. DNA sequence analysis 
revealed that the majority of the clones were identical except 
for the length of 3'-untranslated region. The nucleotide and 
deduced amino acid sequences of the EcoRI insert isolated 
from one of the clones, named hKMOC15, are shown in 
Fig. 1. Analysis of the DNA sequence (nucleotide 1-1999) 
indicated the presence of a single open reading frame (ORF) 
with a predicted initiation codon (ATG) at nucleotide 53 and 
termination at nucleotide 1513 with the stop codon TAG. 
This ORF encodes a polypeptide of 486 amino acid residues 
with a predicted molecular mass of 55 762 Da. The ORF is 
preceded by a 52-nucleotide 5'-untranslated region containing 
no in-frame stop codon and followed by a 489-nucleotide 
untranslated region at the 3'-end. 
3.2. Transient expression of human liver KMO in HEK-293 
cells 
To confirm that the isolated human cDNA indeed encoded 
an enzyme with KMO activity, the human liver hKMOC15 
2.0 kb cDNA was subcloned in the expression vector pBC/ 
CMV [20]. HEK-293 cells, which do not exhibit detectable 
KMO activity, were used for transient transfection. A rela-
tively high level of functional expression of the enzyme was 
observed in the homogenates of the transfected cells. Kinetic 
analysis of recombinant hKMO showed a Km value for L-
kynurenine (13.0 ±3.3 |xM) (Fig. 2) similar to that observed 
by us for the native protein in human liver mitochondrial 
preparations (24.1 ±4.6 uM) (see also Ref. [14]). In addition, 
the KMO inhibitor m-nitrobenzoylalanine [16] inhibited the 
activity of the recombinant enzyme (measured in the presence 
of 50 (J.M L-kynurenine as substrate) with an IC50 value very 
close to that measured for the human enzyme (303 ± 2 and 
332 ± 86 nM (mean ± SEM, n = 3), respectively). 
In accordance with the mitochondrial location of this en-
zyme, an enrichment (approximately 4-fold) in KMO specific 
activity was measured in the crude mitochondrial fraction of 
the transfected cells in comparison to cell homogenate, where-
as in the other subcellular fractions (i.e. nuclei, microsomes 
and cytosol) the enzyme activity detected was much lower (not 
shown). 
3.3. hKMO amino acid sequence analysis 
Comparison of the amino acid sequence of hKMO with 
that deduced for KMO from D. melanogaster, using the 
GAP computer program contained in the Genetics Computer 
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Group sequence analysis software (GCG, version 8, Septem-
ber 1994, University of Wisconsin, USA), indicated 47% and 
66% amino acid identity and similarity, respectively (not 
shown). The N-terminus of the D. melanogaster KMO ap-
pears to be 79 residues longer that the human protein (not 
shown). Analysis of the human enzyme sequence showed the 
presence of three potential iV-glycosylation sites (Asn, Xaa, 
Ser/Thr) at Asn residues 230, 372 and 465. No information, 
however, is presently available as to whether the native pro-
tein is glycosylated. The N-terminal region of hKMO presents 
an AMP/ADP-binding sequence fingerprint (from residue 10-
38 in hKMO) found in NAD- and FAD-dependent enzymes 
[21]. The Gly-x-Gly-x-x-Gly motif (residues 15-20 in hKMO), 
the hydrophobic amino acid residues (positions 11, 13, 24, 27, 
34 and 36) required for the correct fold of the pVa-pV struc-
ture of the dinucleotide binding domain and the acid side-
chain (Glu38) forming an hydrogen bond with the 2'-OH of 
the ribose moiety of FAD, are all present in the hKMO se-
quence. In addition, the fact that this domain is at the N-
terminal of the protein is in accordance with what was found 
for several other known monooxygenases belonging to the 
subclass E 1.14.13 [18]. Analysis of the hydropathy pattern 
of hKMO did not reveal any evident hydrophobic amino 
acid stretch which could be responsible for association to 
the outer mitochondrial membrane. It has been proposed 
that the first 70 residues of the D. melanogaster protein may 
contain the sequence for mitochondrial targeting and/or an-
choring [18]. However, as mentioned above, this sequence 
is absent in hKMO where the N-terminal consists of the 
AMP/ADP binding site. Therefore, the N-terminus of 
hKMO is unlikely to be involved in membrane anchoring. 
Whether, in analogy to e.g. monoamine oxidase, another out-
er membrane mitochondrial protein [22], the C-terminus of 
hKMO, which contains relatively hydrophobic regions, may 
be responsible for mitochondrial anchoring is matter of spec-
ulation. 
3.4. Human KMO sequence comparison 
When the SwissProt (Release 34) and translated EMBL 
database (Release 2) were searched using the program Blast, 
the most significant hits, besides KMO from D. melanogaster, 
were two gene products from Caenorhabditis elegans fprotein 
identification, PID, numbers Q21795 and Q21794) contained 
in the central gene cluster of chromosome III of this nema-
tode, and YBJ8_Yeast, a hypothetical protein in the ATP1-
ROX3 intergenic region of Saccharomyces cerevisiae chromo-
some 2 (accession number Z35859). A multiple alignment of 
the predicted amino acid sequences of hKMO, dmKMO and 
the above mentioned gene products is shown in Fig. 3. Several 
residues were found to be identical or conserved in their phys-
ico-chemical properties in all the sequences, therefore suggest-
ing that these C. elegans and yeast genes encode the corre-
sponding KMO homologues in these organisms. In addition 
to the N-terminal AMP/ADP binding motif, the alignment 
also showed the presence of a highly conserved stretch, includ-
ing the totally conserved sequence GDAAHA (starting at po-
sition 303 in hKMO), which, according to the crystal struc-
ture of the NADPH-dependent flavin monooxygenase 
p-hydroxybenzoate hydroxylase (from Pseudomonas fluo-
rescens; 1PBE in Brookhaven protein data bank), corre-
sponds to the binding site for the riboflavin moiety of FAD 
[23]. It appears, therefore, that the active site of KMO shares 
similar structural features to that of p-hydroxybenzoate hy-
droxylase. 
3.5. Blot hybridization 
A Northern-blot analysis of poly(A)-rich RNAs from var-
ious human tissues is shown in Fig. 4. A major band of ~2 .0 
kb was detected in liver and placenta using the 32P-labeled 
nick-translated PCR-derived 743 bp cDNA probe from 
hKMO. A weaker but detectable band could also be observed 
in kidney whereas in the other tissues, including brain, no 
hybridization signal could be detected under our experimental 
conditions. Overall, these results would indicate a rather spe-
cific expression pattern of the enzyme in the various organs. 
The higher abundance of hKMO mRNA in liver than in 
kidney is in accordance with the enzyme activity levels meas-
ured in these two tissues from humans (unpublished results). 
3.6. Conclusions 
The successful cloning of human KMO will allow the in-
vestigation of several aspects of enzyme function, including 
the regulation of its expression in pathophysiological condi-
tions. In addition, it will enable the production of the enzyme 
in sufficient quantities for further structural and functional 
analysis. Due to the growing interest in KMO inhibitors as 
potential neuroprotective agents, this will be instrumental for 
the rational design of potent and selective KMO inhibitors. 
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